Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers

References

• Dubowitz V Prednisone for Duchenne muscular dystrophy Lancet Neurol 2005 4 5 264 15847833
   PubMed Web of Science ®Google Scholar
• Ruegg UT Pharmacological prospects in the treatment of Duchenne muscular dystrophy Curr Opin Neurol 2013 26 5 577 584 23995279
   PubMed Web of Science ®Google Scholar
• Jarmin S Kymalainen H Popplewell L Dickson G New developments in the use of gene therapy to treat Duchenne muscular dystrophy Expert Opin Biol Ther 2014 14 2 209 230 24308293
   PubMed Web of Science ®Google Scholar
• Pichavant C Aartsma-Rus A Clemens PR Current status of pharmaceutical and genetic therapeutic approaches to treat DMD Mol Ther 2011 19 5 830 840 21468001
   PubMed Web of Science ®Google Scholar
• Liu N Williams AH Maxeiner JM microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice J Clin Invest 2012 122 6 2054 2065 22546853
   PubMed Web of Science ®Google Scholar
• Wang L Zhou L Jiang P Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis Mol Ther 2012 20 6 1222 1233 22434133
   PubMed Web of Science ®Google Scholar
• Malik V Rodino-Klapac LR Viollet L Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy Ann Neurol 2010 67 6 771 780 20517938
   PubMed Web of Science ®Google Scholar
• Wehling M Spencer MJ Tidball JG A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice J Cell Biol 2001 155 1 123 131 11581289
   PubMed Web of Science ®Google Scholar
• Rando TA Role of nitric oxide in the pathogenesis of muscular dystrophies: a “two hit” hypothesis of the cause of muscle necrosis Microsc Res Tech 2001 55 4 223 235 11748861
   PubMed Web of Science ®Google Scholar
• Kobayashi YM Rader EP Crawford RW Sarcolemma-localized nNOS is required to maintain activity after mild exercise Nature 2008 456 7221 511 515 18953332
   PubMed Web of Science ®Google Scholar
• Lai Y Thomas GD Yue Y Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy J Clin Invest 2009 119 3 624 635 19229108
   PubMed Web of Science ®Google Scholar
• Stamler JS Meissner G Physiology of nitric oxide in skeletal muscle Physiol Rev 2001 81 1 209 237 11152758
   PubMed Web of Science ®Google Scholar
• Nisoli E Clementi E Paolucci C Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide Science 2003 299 5608 896 899 12574632
   PubMed Web of Science ®Google Scholar
• Wehling-Henricks M Oltmann M Rinaldi C Myung KH Tidball JG Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy Hum Mol Genet 2009 18 18 3439 3451 19542095
   PubMed Web of Science ®Google Scholar
• Anderson JE A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells Mol Biol Cell 2000 11 5 1859 1874 10793157
   PubMed Web of Science ®Google Scholar
• Cazzato D Assi E Moscheni C Nitric oxide drives embryonic myogenesis in chicken through the upregulation of myogenic differentiation factors Exp Cell Res 2014 320 2 269 280 24240125
   PubMed Web of Science ®Google Scholar
• Colussi C Mozzetta C Gurtner A HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment Proc Natl Acad Sci U S A 2008 105 49 19183 19187 19047631
   PubMed Web of Science ®Google Scholar
• Percival JM Anderson KN Gregorevic P Chamberlain JS Froehner SC Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice PLoS One 2008 3 10 e3387 18852886
   PubMed Web of Science ®Google Scholar
• Filippin LI Moreira AJ Marroni NP Xavier RM Nitric oxide and repair of skeletal muscle injury Nitric Oxide 2009 21 3–4 157 163 19682596
   PubMed Web of Science ®Google Scholar
• De Palma C Clementi E Nitric oxide in myogenesis and therapeutic muscle repair Mol Neurobiol 2012 46 3 682 692 22821188
   PubMed Web of Science ®Google Scholar
• Buono R Vantaggiato C Pisa V Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP Stem Cells 2012 30 2 197 209 22084027
   PubMed Web of Science ®Google Scholar
• Cordani N Pisa V Pozzi L Sciorati C Clementi E Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation Stem CellsEpub 10 29 2013
   Google Scholar
• Brunelli S Sciorati C D’Antona G Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy Proc Natl Acad Sci U S A 2007 104 1 264 269 17182743
   PubMed Web of Science ®Google Scholar
• Sciorati C Miglietta D Buono R A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy Pharmacol Res 2011 64 3 210 217 21609764
   PubMed Web of Science ®Google Scholar
• Sciorati C Staszewsky L Zambelli V Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure Pharmacol Res 2013 73 35 43 23644256
   PubMed Web of Science ®Google Scholar
• Sciorati C Buono R Azzoni E Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans Br J Pharmacol 2010 160 6 1550 1560 20590643
   PubMed Web of Science ®Google Scholar
• D’Angelo MG Gandossini S Martinelli Boneschi F Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients Pharmacol Res 2012 65 4 472 479 22306844
   PubMed Web of Science ®Google Scholar
• Fung HL McNiff EF Ruggirello D Darke A Thadani U Parker JO Kinetics of isosorbide dinitrate and relationships to pharmacological effects Br J Clin Pharmacol 1981 11 6 579 589 7272174
   PubMed Web of Science ®Google Scholar
• Bushra R Aslam N An overview of clinical pharmacology of ibuprofen Oman Med J 2010 25 3 155 161 22043330
   PubMedGoogle Scholar
• Farrar H Letzig L Gill M Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma J Chromatogr B Analyt Technol Biomed Life Sci 2002 780 2 341 348
   PubMed Web of Science ®Google Scholar
• Zhao X Chen D Li K Wang D Sensitive liquid chromatographic assay for the simultaneous determination of ibuprofen and its prodrug, ibuprofen eugenol ester, in rat plasma Yakugaku Zasshi 2005 125 9 733 737 16141693
   PubMed Web of Science ®Google Scholar
• Verma RK Garg S A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations J Pharm Biomed Anal 2002 30 3 583 591 12367683
   PubMed Web of Science ®Google Scholar
• Stockis A De Bruyn S Deroubaix X Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab) Eur J Pharm Biopharm 2002 53 1 49 56 11777752
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM) Guidance for Industry: Bioanalytical Method Validation Rockville, MD Center for Drug Evaluation and Research (CDER) 2001 Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed January 10, 2013
   Google Scholar
• European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP) Guideline on the Investigation of Bioequivalence London, UK European Medicines Agency 2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf Accessed January 10, 2013
   Google Scholar
• Finanger Hedderick EL Simmers JL Soleimani A Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders Neurology 2011 76 11 960 967 21403107
   PubMed Web of Science ®Google Scholar